drugset / Trial / NCT00936819
The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial
Phase 2
Active not recruiting
47 enrolled
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR) · collabStem Cell Network · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This will be the first clinical trial to include a strategy designed to enhance the function of autologous progenitor cells by overexpressing eNOS, and the first to use combination gene and cell therapy for the treatment of cardiac disease.
Timeline
- Start
- 2013-07-19
- Primary completion
- 2020-03-05
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous EPCs | Unknown | 20 cells | Other |
| Subject | Autologous EPCs Transfected with human eNOS | Unknown | 20 cells | Other |